Phase 2 Study to Evaluate the Microbiology and Safety of C16G2 Administered to Adult and Adolescent Dental Subjects

NCT ID: NCT02594254

Last Updated: 2019-08-01

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 135 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2015-11-30
• Study Completion Date: 2016-09-30

Brief Summary

The purpose of this study is to evaluate if C16G2 Gel administered over a certain period of time either with a toothbrush or a custom dental tray can effectively kill bacteria in the mouth that cause dental cavities.

Detailed Description

This multi-center, multiple-arm study will evaluate the microbiological activity and safety of C16G2 Gel in male and female dental subjects, 12 to 75 years of age. The study will be conducted in a randomized, double-blind, placebo-controlled and open-label manner and enroll adolescent (12-17 years of age) and adult subjects (18-75 years of age).

A total of approximately 128 study subjects will be enrolled into up to 7 study arms. Study drug (C16G2 Gel or Placebo) will be administered via manual brush gel application (MBGA) or tray gel application (TGA). Two C16G2 concentrations will be evaluated. Four study arms will be conducted in a double blind manner, with a treatment allocation ratio of 4:1 (C16G2:Placebo), three study arms will be conducted in an open-label manner. Before dosing, eligible subjects will undergo professional dental prophylaxis on Day 0. Clinic visits for all study arms will include Visit 1 (Screening/Days -21 to 0), and a varying number of dosing and follow-up visits.

Conditions

Dental Caries

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Study Arm 1

Subjects in Study Arm 1 will receive 4 ml of 800 µM study drug administrations for a total of 28 consecutive days. Subjects will receive 4 C16G2 Gel or placebo administrations at the clinic on the first day, followed by morning (AM) and evening (PM) study drug administrations at the subjects' home for 27 consecutive days. Study drug will be administered via a manual brush.

Group Type: EXPERIMENTAL

C16G2 Gel

Intervention Type: DRUG

Antimicrobial peptide

Placebo

Intervention Type: OTHER

Placebo

Study Arm 2

Subjects in Study Arm 2 will receive 4 ml of 800 µM study drug administrations for a total of 28 consecutive days. Subjects will receive 4 C16G2 Gel or placebo administrations at the clinic on the first day, followed by morning (AM) and evening (PM) study drug administrations at the subjects' home for 27 consecutive days. Study drug will be administered via a manual brush and custom dental trays.

Group Type: EXPERIMENTAL

C16G2 Gel

Intervention Type: DRUG

Antimicrobial peptide

Placebo

Intervention Type: OTHER

Placebo

Study Arm 3

Subjects in open-label Study Arm 3 will receive 4 ml of 1600 µM study drug administrations for a total of 7 consecutive days. Subjects will receive 4 C16G2 Gel administrations at the clinic on the first day, followed by morning (AM) and evening (PM) study drug administrations at the clinic for 6 consecutive days. Study drug will be administered via a manual brush and custom dental trays.

Group Type: EXPERIMENTAL

C16G2 Gel

Intervention Type: DRUG

Antimicrobial peptide

Study Arm 4

Subjects in open-label Study Arm 4 will receive 4 ml 800 µM C16G2 Gel on a single day. Subjects will receive 4 study drug administrations at the clinic. Study drug will be administered via manual toothbrush and custom dental trays.

Group Type: EXPERIMENTAL

C16G2 Gel

Intervention Type: DRUG

Antimicrobial peptide

Study Arm 5

Subjects in open-label Study Arm 4 will receive 4 ml of 1600 µM C16G2 Gel on a single day. Subjects will receive 4 study drug administrations at the clinic. Study drug will be administered via manual toothbrush and custom dental trays.

Group Type: EXPERIMENTAL

C16G2 Gel

Intervention Type: DRUG

Antimicrobial peptide

Study Arm 6

If initiated, subjects in Study Arm 6 will receive 4 ml of 1600 µM study drug over a 7 day study drug administration period. Subjects will receive 4 C16G2 Gel or placebo administrations on the first day of dosing followed by morning (AM) and evening (PM) dosing for 6 consecutive days. Study drug will be administered via manual toothbrush and custom dental trays.

Group Type: EXPERIMENTAL

C16G2 Gel

Intervention Type: DRUG

Antimicrobial peptide

Placebo

Intervention Type: OTHER

Placebo

Study Arm 7

If initiated, subjects in Study Arm 7 will receive 4 ml of 800 µM or 1600 µM study drug on a single day once a week or once a month for a total of 4 days of C16G2 Gel or placebo administration. Subjects will receive 4 study drug administrations on the day of dosing. Study drug will be administered via manual toothbrush and custom dental trays.

Group Type: EXPERIMENTAL

C16G2 Gel

Intervention Type: DRUG

Antimicrobial peptide

Placebo

Intervention Type: OTHER

Placebo

Interventions

C16G2 Gel

Antimicrobial peptide

Intervention Type: DRUG

Placebo

Placebo

Intervention Type: OTHER

Other Intervention Names

Antimicrobial peptide

Eligibility Criteria

Inclusion Criteria

1. Males and females, 12-75 years of age, inclusive, at the time the Assent and/or Informed Consent Form is signed

2. Female subjects of childbearing potential, defined as not surgically sterile or at least two (2) years postmenopausal, must agree to use one of the following forms of contraception from screening through the last study visit: hormonal (oral, implant, or injection) begun >30 days prior to screening; barrier (condom, diaphragm, or cervical cap with spermicide); intrauterine device (IUD). Acceptable contraceptive options may also include abstinence, relationship with same sex partner or partner who has had a vasectomy at least six (6) months prior to the screening visit

3. Male subjects only: willing to use contraception or abstain from sexual activity beginning with the first exposure to study drug and continuing until discharged from the study due to completion or Early Termination

4. Healthy, as determined by the Investigator (in consultation with the Medical Monitor, as needed), based on medical and dental history, concurrent illnesses, laboratory results, concomitant medications, oral cavity assessment, and targeted physical examination (extraoral, head and neck) during Screening Note: Subjects on a stable dose of medication may be eligible for screening and will be assessed by the Medical Monitor on a case-by-case basis.

5. Have a minimum of 12 bicuspids and molars with a minimum of 8 molars and bicuspids NOT having restorations, crowns, sealants

6. Demonstrated ability to expectorate ≥2 mL of stimulated saliva in 5 minutes

7. Have a salivary S. mutans of 1.0 x 10^5 colony forming units (CFUs)/mL or greater at Screening using mitis salivarius-bacitracin (MSB) agar plating

8. Willing to refrain from using non-study dentifrice and other non-study oral care products (oral care rinses, fluoride products, etc.) during the study

9. Willing to postpone elective dental procedures (e.g., dental cleanings) between Screening and final post-treatment visit (End of Study or Early Termination)

10. Willing and able to comply with oral hygiene and diet instructions

11. Has dentition adequate for custom dental tray gel application

12. Able to understand and sign the Assent and/or Informed Consent Form prior to initiation of study procedures

13. Able to communicate with the Investigator/study center personnel, understand and comply with the study requirements, and willing to return for protocol-specified visits at the appointed times

Exclusion Criteria

1. Advanced periodontal disease

2. Active caries lesion(s) within 30 days prior to study drug administration (confirmed by comprehensive caries examination including standard radiographs if deemed necessary by the Investigator) Note: Subjects presenting with insipient, non-cavitated lesion(s) are not excluded

3. Medical condition (e.g., artificial heart valve, history of infective endocarditis, cardiac transplant with valvular dysfunction, congenital heart disease or total joint replacement) for which antibiotics are recommended prior to dental visits and/or procedures

4. Pathologic lesions of the oral cavity (suspicious or confirmed)

5. Full dentures or orthodontic appliances, e.g., braces; Note: partial dentures, removable retainers and night guards are not excluded, provided that they are cleaned regularly throughout the duration of the study.

6. Use of systemic antibiotics, topical oral antibiotics, or use of other drugs, which in the opinion of the Investigator could influence the study outcome, within 30 days prior to Screening and throughout the entire study.

7. Medical history indicating the woman is pregnant, breastfeeding/lactating or has a positive urine pregnancy test

8. Participation in a clinical trial or receipt of a non-FDA approved therapy within 30 days prior to study drug administration (depending on the specifics, participation in an observational study is not necessarily excluded)

9. Prior participation in a C16G2 clinical trial and known to have received C16G2 active gel or mouth rinse Note: Placebo subjects are not excluded

10. Presence of any condition or concurrent illness, which in the opinion of the Investigator, would compromise normal immune function (e.g., diabetes, rheumatoid arthritis, lupus, liver disease, organ transplant, etc.), interfere with the use of study dentifrice and oral care products, or interfere with the ability to comply with study requirements, or jeopardize the safety of the subject or the validity of the study results

• Minimum Eligible Age: 12 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Vantage Data Designs, Inc.

INDUSTRY

Sponsor Role: collaborator

SynteractHCR

INDUSTRY

Sponsor Role: collaborator

Agility Clinical, Inc.

INDUSTRY

Sponsor Role: collaborator

Armata Pharmaceuticals, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Mark Wolff, DDS, PhD

Role: PRINCIPAL_INVESTIGATOR

NYU Langone Health

Locations

Imperial Beach Family Dentistry

Imperial Beach, California, United States

Indiana University School of Dentistry

Indianapolis, Indiana, United States

Tufts University

Boston, Massachusetts, United States

John F. Pittaway, DMD

Kalispell, Montana, United States

Plaza West II Dental Group

Kalispell, Montana, United States

New York University College of Dentistry

New York, New York, United States

East Carolina University

Greenville, North Carolina, United States

University of Pennsylvania School of Dental Medicine

Philadelphia, Pennsylvania, United States

Texas Baylor College of Dentistry

Dallas, Texas, United States

Anthony Henegar, DDS, PA

Irving, Texas, United States

Countries

United States

Other Identifiers

C3J15-203-00

Identifier Type: -

Identifier Source: org_study_id